Pharmaceuticals

Oral Biologics & Biosimilar Drugs Market 2026 showing strong expansion potential, reaching $17.17 billion by 2030

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Oral Biologics & Biosimilar Drugs Market Evolve From 2026 To 2030?

The oral biologics & biosimilar drugs market has seen substantial expansion in recent years. This market is expected to increase from $8.6 billion in 2025 to $10.41 billion in 2026, achieving a compound annual growth rate (CAGR) of 21.0%. The historical development in this sector can be ascribed to several factors, including the limited supply of oral biologics, a past reliance on injectable biologics, the rising incidence of autoimmune and inflammatory conditions, increasing patient demand for cost-effective treatments, and the early approvals of monoclonal antibody drugs.

The oral biologics & biosimilar drugs market is projected to experience substantial expansion over the upcoming years. This market is set to reach $17.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.3%. This projected increase during the forecast period is fueled by several factors, including the advancement of next-generation oral biologics, the widening scope of the biosimilar pipeline, a surge in the embrace of combination therapies, the proliferation of digital health platforms for patient oversight, and heightened regulatory encouragement for biosimilar approvals. Key developments anticipated during this period encompass the growing acceptance of oral biologics and biosimilar drugs, an intensified focus on managing chronic diseases with biologics, the broadening of hospital and retail pharmacy distribution networks, improved patient understanding and acceptance of biosimilars, and the creation of targeted therapies for autoimmune and inflammatory conditions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp

What Major Drivers Are Influencing Demand In The Oral Biologics & Biosimilar Drugs Market?

The increasing occurrence of chronic illnesses like arthritis, asthma, and cancer is anticipated to be a significant factor propelling the oral biologics and biosimilar market. Lifestyle factors such as extended work hours, insufficient physical movement, and poor dietary habits contribute to these chronic conditions, which are progressively being managed with biologics. Biologics function by stimulating the immune system to target cancer cells, thereby aiding the body in their removal. A United Nations article from May 2023 highlighted that by 2030, chronic diseases are projected to account for 70% of all global deaths. The worldwide impact of chronic disease is also foreseen to reach approximately 60%. Consequently, the growing incidence of chronic diseases is expected to boost the demand for biologics and biosimilars, thereby fueling the expansion of the oral biologics & biosimilar drugs market.

Which Segment Areas Are Covered In The Oral Biologics & Biosimilar Drugs Market Analysis?

The oral biologics & biosimilar drugs market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors

2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others

3) By Molecule Type: Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab

2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab

3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab

What Key Developments And Trends Are Impacting The Oral Biologics & Biosimilar Drugs Market?

Major companies in the oral biologics and biosimilar markets are focusing on innovative products, such as incretin triagonists, to improve patient outcomes, enhance drug efficacy, and provide alternatives to injectable therapies. Incretin triagonists are medications that simultaneously activate three hormone receptors, namely GLP-1, GIP, and glucagon, which play a role in regulating blood sugar, appetite, and metabolism. For instance, in October 2024, Rani Therapeutics Holdings Inc., a US-based biotechnology company, released new preclinical pharmacokinetic data supporting the transenteric delivery of a GLP-1 incretin triagonist. Their RaniPill, an oral capsule designed for delivering biologics that traditionally require injections, successfully administered an incretin triagonist targeting GLP-1, GIP, and glucagon receptors, which are key targets in obesity treatment. The RaniPill demonstrated effectiveness comparable to subcutaneous injections, offering a needle-free alternative with high bioavailability and flexible dosing, thereby establishing it as a promising solution for obesity drug candidates.

Which Global Companies Are Actively Competing In The Oral Biologics & Biosimilar Drugs Market?

Major companies operating in the oral biologics & biosimilar drugs market are Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., GlaxoSmithKline PLC, Concord Biotech Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.

Read the full oral biologics & biosimilar drugs market report here:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Oral Biologics & Biosimilar Drugs Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest growing region in the oral biologics & biosimilar drugs market report during the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oral Biologics & Biosimilar Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3792&type=smp

Browse Through More Reports Similar to the Global Oral Biologics & Biosimilar Drugs Market 2026, By The Business Research Company

Dental Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/dental-services-global-market-report

Dental Practice Management Market Report 2026

https://www.thebusinessresearchcompany.com/report/dental-practice-management-global-market-report

Dental X Ray Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/dental-x-ray-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795